We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Phimedix Plc | LSE:PHM | London | Ordinary Share | GB00BLM14N85 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.95 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMPHM
RNS Number : 7997Y
Phimedix PLC
11 September 2020
11 September 2020
Phimedix Plc
("Phimedix" or "the Company")
Notice of Annual General Meeting and AIM Rule 15 Update
Phimedix (AIM: PHM) confirms that the Annual Report & Accounts for the year ended 31 March 2020, together with the Notice of its Annual General Meeting ("AGM") and Form of Proxy, have been posted to shareholders and are available on the Company's website www.phimedix.com . The AGM is to be held at 10.00 a.m. on 5 October 2020, at Bracher Rawlins LLP, 77 Kingsway, London WC2B 6SR.
In accordance with Government legislation and related restrictions in response to COVID-19, and to minimise public health risks, the General Meeting is to be held as a closed meeting unless both the coronavirus (COVID-19) situation and the applicable guidance have changed prior to the date of the meeting. Unless Shareholders are notified otherwise by the Company prior to the date of the General Meeting, the arrangements for the meeting shall be that neither Shareholders, nor their proxies nor corporate representatives will be permitted to attend the meeting in person. As such, Shareholders are strongly encouraged to appoint the Chairman of the General Meeting to act as their proxy as no other person will be permitted to attend the meeting.
AIM Rule 15 update
The London Stock Exchange is expected to suspend trading in the Company's ordinary shares on AIM, pursuant to Rule 15 of the AIM Rules, at 7.30 am on 14 September 2020. In the event that no reverse takeover is completed in the six months after that date, the London Stock Exchange will cancel the admission of the Company's ordinary shares to trading on AIM.
Phimedix Plc Please email any enquiries Nicholas Nelson, Director to nelson@nexfin.org.uk Ajay Rajpal, Director SPARK Advisory Partners Limited (Nominated Adviser) Mark Brady or Neil Baldwin www.sparkadvisorypartners.com +44 (0) 203 368 3550 SI Capital Ltd (Broker) Nick Emerson www.sicapital.co.uk +44 (0)1483 413500
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NOAGPUUWBUPUGCG
(END) Dow Jones Newswires
September 11, 2020 10:33 ET (14:33 GMT)
1 Year Phimedix Chart |
1 Month Phimedix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions